Brief: Gilead Sciences Inc reports 14.8% passive stake in Allovir
Aug 8 (Reuters) -
* GILEAD SCIENCES INC REPORTS 14.8% PASSIVE STAKE IN ALLOVIR
INC
AS OF JULY 28 - SEC FILING
Further company coverage: ALVR.O
(Reporting by Priyamvada C)
((Priyamvada.C@thomsonreuters.com;))
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million